Published in Clin Cancer Res on December 01, 2001
The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol (2011) 1.55
Mitochondria: pharmacological manipulation of cell death. J Clin Invest (2005) 1.54
Apoptosis and molecular targeting therapy in cancer. Biomed Res Int (2014) 1.47
FOXA1: master of steroid receptor function in cancer. EMBO J (2011) 1.36
Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study. Invest New Drugs (2006) 0.99
Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC). Invest New Drugs (2005) 0.98
The changing landscape in the treatment of metastatic castration-resistant prostate cancer. Ther Adv Med Oncol (2013) 0.97
YB-1 is a Transcription/Translation Factor that Orchestrates the Oncogenome by Hardwiring Signal Transduction to Gene Expression. Transl Oncogenomics (2007) 0.96
Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer. Clin Cancer Res (2008) 0.91
Why anti-Bcl-2 clinical trials fail: a solution. Cancer Metastasis Rev (2014) 0.84
Therapeutic efficacy of adenoviral-mediated p53 gene transfer is synergistically enhanced by combined use of antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Neoplasia (2005) 0.82
A phase I pharmacokinetic and pharmacodynamic correlative study of the antisense Bcl-2 oligonucleotide g3139, in combination with carboplatin and paclitaxel, in patients with advanced solid tumors. Clin Cancer Res (2008) 0.81
Survivin antisense oligodeoxynucleotide inhibits growth of gastric cancer cells. World J Gastroenterol (2004) 0.80
A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patients with advanced solid cancers. Invest New Drugs (2006) 0.79
Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand? Cell Death Dis (2016) 0.77
Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies. Invest New Drugs (2010) 0.77
Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancer. World J Urol (2005) 0.76
A phase I trial of oblimersen sodium in combination with cisplatin and 5-fluorouracil in patients with advanced esophageal, gastroesophageal junction, and gastric carcinoma. Am J Clin Oncol (2010) 0.76
Epigenetic therapy in urologic cancers: an update on clinical trials. Oncotarget (2016) 0.75
New therapeutic targets in the treatment of prostate cancer. Indian J Urol (2007) 0.75
Lambda replacement vectors carrying polylinker sequences. J Mol Biol (1983) 32.76
Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer (1994) 3.25
Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial. J Clin Oncol (1988) 2.91
Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre. J Natl Cancer Inst (1997) 2.52
Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome. Lancet (1981) 2.36
Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol (2003) 2.16
Patterns of failure following loco-regional radiotherapy in the treatment of limited stage small cell lung cancer. Int J Radiat Oncol Biol Phys (1994) 2.01
Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. J Clin Oncol (1990) 1.88
'Settings' based health promotion: a review. Health Promot Int (2001) 1.87
Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood (1997) 1.85
Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J Urol (2004) 1.73
Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol (2005) 1.67
Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. J Steroid Biochem Mol Biol (1996) 1.61
A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol (2006) 1.51
Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology (1995) 1.50
The influence of disclosure of HIV diagnosis on time to disease progression in a cohort of Romanian children and teens. AIDS Care (2007) 1.49
Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study. Br J Cancer (2005) 1.49
A sequence pattern for peptides presented to cytotoxic T lymphocytes by HLA B8 revealed by analysis of epitopes and eluted peptides. Eur J Immunol (1993) 1.48
Small cell carcinoma of the bladder: long term outcome with integrated chemoradiation. Cancer (1999) 1.43
Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res (2000) 1.41
In situ replacement of the aorta in a contaminated field with the infrarenal inferior vena cava. J Vasc Surg (1999) 1.39
Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada. Ann Intern Med (1987) 1.38
Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP. J Biol Chem (1997) 1.38
Parental influences on students' aggressive behaviors and weapon carrying. Health Educ Behav (1999) 1.37
Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res (2000) 1.35
Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Ann Oncol (2009) 1.33
Demyelinating neuropathy and monoclonal IgM antibody to myelin-associated glycoprotein. Neurology (1983) 1.33
Crescentic glomerulonephritis: a possible complication of streptokinase treatment for myocardial infarction. Br Heart J (1986) 1.33
Dissemination and adoption of the Child and Adolescent Trial for Cardiovascular Health (CATCH): a case study in Texas. J Public Health Manag Pract (2001) 1.32
Lambda phage vectors--EMBL series. Methods Enzymol (1987) 1.28
Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol (1997) 1.25
Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised. J Exp Med (1995) 1.25
Dietary trends among Scottish schoolchildren in the 1990s. J Hum Nutr Diet (2001) 1.21
Peripheral neuropathy associated with monoclonal IgM autoantibody. Ann Neurol (1987) 1.20
Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann Oncol (2009) 1.19
Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations. Mol Urol (2000) 1.17
Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy. Ann Oncol (2009) 1.16
Managing late-life depression in primary care practice: a case study of the Health Specialist's role. Int J Geriatr Psychiatry (2001) 1.15
Small noncleaved, non-Burkitt's (Burkit-Like) lymphoma: cytogenetics predict outcome and reflect clinical presentation. J Clin Oncol (1999) 1.15
Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3'-kinase pathway. Endocrinology (2000) 1.13
Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry. J Pharmacol Exp Ther (2001) 1.12
Outcome evaluation of a multi-component violence-prevention program for middle schools: the Students for Peace project. Health Educ Res (2000) 1.11
Human monoclonal antibodies to myelin-associated glycoprotein. Comparison of specificity and use for immunocytochemical localisation of the antigen. J Neuroimmunol (1983) 1.10
A retrospective mortality study within operating segments of a petroleum company. Am J Ind Med (1992) 1.10
Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. J Natl Cancer Inst (2000) 1.10
The role of prophylactic brain irradiation in limited stage small cell lung cancer: clinical, neuropsychologic, and CT sequelae. Int J Radiat Oncol Biol Phys (1988) 1.08
A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice. Cancer Res (1997) 1.08
Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. Ann Oncol (2006) 1.07
HMO market structure and performance: 1985-1995. Health Aff (Millwood) (1998) 1.07
Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J Clin Oncol (1991) 1.06
Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline. Cancer Res (1993) 1.05
Influence of age on the treatment of limited-stage small-cell lung cancer. J Clin Oncol (1996) 1.05
Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Clin Cancer Res (2001) 1.05
Undisplaced intracapsular hip fractures in the elderly: predicting fixation failure and mortality. A prospective study of 162 patients. J Orthop Sci (2013) 1.05
Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells. Cancer Res (2000) 1.04
Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model. Cancer Res (1999) 1.03
Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (1999) 1.03
Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol (1999) 1.02
Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Neoplasia (2001) 1.02
Insecticide-treated clothes for the control of vector-borne diseases: a review on effectiveness and safety. Med Vet Entomol (2014) 1.02
t(11;18)(q21;q21.1): a recurring translocation in lymphomas of mucosa-associated lymphoid tissue (MALT)? Genes Chromosomes Cancer (1992) 1.00
Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapies. Ann Oncol (2010) 0.99
Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells. Cancer Res (1996) 0.99
Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer. Br J Cancer (2011) 0.99
Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. J Clin Oncol (1996) 0.98
Limited-stage mantle-cell lymphoma. Ann Oncol (2003) 0.98
Lambert-Eaton myasthenic syndrome: electrophysiological evidence for a humoral factor. Muscle Nerve (1982) 0.98
GRP78 regulates clusterin stability, retrotranslocation and mitochondrial localization under ER stress in prostate cancer. Oncogene (2012) 0.98
Human prostate cancer model: roles of growth factors and extracellular matrices. J Cell Biochem Suppl (1992) 0.98
Retrospective benzene and total hydrocarbon exposure assessment for a petroleum marketing and distribution worker epidemiology study. Am Ind Hyg Assoc J (1996) 0.96
Introduction of clusterin gene into human renal cell carcinoma cells enhances their resistance to cytotoxic chemotherapy through inhibition of apoptosis both in vitro and in vivo. Jpn J Cancer Res (2001) 0.95
Retroperitoneal lymphadenectomy for post-chemotherapy residual masses: is a modified dissection and resection of residual masses sufficient? Br J Urol (1998) 0.95
Inflammatory pseudotumor of the urinary bladder: a report of five cases and review of the literature. Can J Urol (2001) 0.94
Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res (2000) 0.94
Mortality and cancer morbidity in a cohort of Canadian petroleum workers. Occup Environ Med (2003) 0.94
Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α5β1 integrin monoclonal antibody (volociximab) in cancer patients. Cancer Chemother Pharmacol (2010) 0.93
Low-resolution structure of the glycogen phosphorylase alpha monomer and comparison with phosphorylase beta. J Mol Biol (1976) 0.93
The influence of age on the delivery, tolerance, and efficacy of thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer. Int J Radiat Oncol Biol Phys (1999) 0.93
Overexpression of the cytoprotective protein clusterin decreases radiosensitivity in the human LNCaP prostate tumour model. BJU Int (2003) 0.92
Indication of a possible role in a demyelinating neuropathy for an antigen shared between myelin and NK cells. Lancet (1984) 0.92
Hsp27 silencing coordinately inhibits proliferation and promotes Fas-induced apoptosis by regulating the PEA-15 molecular switch. Cell Death Differ (2011) 0.92
What proportion of patients with myocardial infarction are suitable for thrombolysis? Br Heart J (1987) 0.92
Concurrent translocation of BCL2 and MYC with a single immunoglobulin locus in high-grade B-cell lymphomas. Leukemia (2005) 0.91
Updated mortality among diverse operating segments of a petroleum company. Occup Environ Med (2000) 0.91
International multicentre study examining selection criteria for active surveillance in men undergoing radical prostatectomy. Br J Cancer (2012) 0.90
The 2000 EBCTCG overview: a widening gap. Lancet (2005) 0.89
A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer. Ann Oncol (2009) 0.89
A variable dextrose delivery system for neonatal intensive care. Arch Dis Child Fetal Neonatal Ed (1994) 0.89
Expression of a single-chain HLA class I molecule in a human cell line: presentation of exogenous peptide and processed antigen to cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (1996) 0.89
Reciprocal mesenchymal-epithelial interaction affecting prostate tumour growth and hormonal responsiveness. Cancer Surv (1991) 0.88
Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers. Curr Cancer Drug Targets (2006) 0.88
Mechanisms of loss of HLA class I expression on colorectal tumor cells. Tissue Antigens (1996) 0.88
A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer. Ann Oncol (2005) 0.88
Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model. Br J Cancer (2012) 0.88
Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors. J Clin Oncol (2000) 0.87
Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model. Int J Cancer (2001) 0.87
Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity. Ann Oncol (2004) 0.87